openPR Logo
Press release

Ovarian Cancer - Pipeline Review, H1 2017

07-17-2017 02:59 PM CET | Health & Medicine

Press release from: Report Hive

Ovarian Cancer

Ovarian Cancer

Report Hive Market Research Released a New Research Report of 2027 pages on Title " Ovarian Cancer - Pipeline Review, H1 2017 "with detailed Analysis, Forecast and Strategies.

Ovarian Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Request Free Research Sample: https://www.reporthive.com/request-sample.php?id=931476

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 15, 135, 128, 7, 208, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 14, 43 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 12
Ovarian Cancer - Overview 13
Ovarian Cancer - Therapeutics Development 14
Ovarian Cancer - Therapeutics Assessment 73
Ovarian Cancer - Companies Involved in Therapeutics Development 105
Ovarian Cancer - Drug Profiles 254
Ovarian Cancer - Dormant Projects 1928
Ovarian Cancer - Discontinued Products 1947
Ovarian Cancer - Product Development Milestones 1951
Appendix 1968

Browse Full Report: https://www.reporthive.com/details/ovarian-cancer-pipeline-review-h1-2017

Key questions answered in the report

· What will the market size and the growth rate be in 2021?
· What are the key factors driving the Ovarian Cancer Market?
· What are the key market trends impacting the growth of the Ovarian Cancer Market?
· What are the challenges to market growth?
· Who are the key vendors in this market space?
· What are the market opportunities and threats faced by the vendors in the Ovarian Cancer Market?
· Trending factors influencing the market shares of the Americas, APAC, and EMEA?
· What are the key outcomes of the five forces analysis of the Ovarian Cancer Market?

We are a leading repository of market research reports and solutions catering to industries like Comm & Technology, Energy & Power, Food And Beverages, Automotive & Transportation, Healthcare & Life Science etc. This large collection of reports assists organizations in decision-making on aspects such as market entry strategies, market sizing, market share analysis, competitive analysis, product portfolio analysis and opportunity analysis among others. We also assist in determining the best suited and targeted report from our large repository of global reports, company-specific reports and country-level reports.

Mike Ross
Marketing Manager
mike.ross@reporthive.com
http://www.reporthive.com
Phone: +1 312-604-7084
Sainath Nagar, Vadgaon Sheri,
Pune, Maharashtra 411014

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ovarian Cancer - Pipeline Review, H1 2017 here

News-ID: 627705 • Views: 238

More Releases from Report Hive

Corporate Performance Management (CPM) Software Market 2019: By Adaptive Insight …
According to this study, over the next five years the Corporate Performance Management (CPM) Software market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Corporate Performance Management (CPM) Software business, shared in Chapter 3. This report presents a comprehensive
Investment Management Solutions Market 2019: Misys, SS&C Tech, SimCorp, Eze Soft …
According to this study, over the next five years the Investment Management Solutions market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Investment Management Solutions business, shared in Chapter 3. This report presents a comprehensive overview, market shares and
Social Customer Service Software Market 2019: Zendesk, Salesforce, Freshworks, S …
According to this study, over the next five years the Social Customer Service Software market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Social Customer Service Software business, shared in Chapter 3. This report presents a comprehensive overview, market
Auto Loan Origination Software Market 2019: DH Corp, Lending QB, Black Knight, I …
According to this study, over the next five years the Auto Loan Origination Software market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Auto Loan Origination Software business, shared in Chapter 3. This report presents a comprehensive overview, market

All 5 Releases


More Releases for Ovarian

Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).
Polycystic Ovarian Syndrome - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Polycystic Ovarian Syndrome - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape. Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms
Ovarian Cancer Drugs Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Ovarian Cancer Drugs Market Report : 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/united-states-ovarian-cancer-drugs-market-report-2017-1541150 In this report, the United States Ovarian Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in
Latest Report: Global Ovarian Cancer Market 2017
MarketResearchReports.Biz presents this most up-to-date research on "Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017" DelveInsights, Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017, report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the ovarian cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape
Ovarian Cancer - Heat Map and Analysis
Albany, NY, Feb 27, 2017: Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in the treatment of OC have been made in recent decades, through the introduction of platinum-based compounds, and improvements in surgery. This has